Oritavancin Diphosphate

Oritavancin Diphosphate (CAS No.: 192564-14-0) is a semisynthetic glycopeptide antibacterial research compound, commonly referenced as LY333328 diphosphate, that is categorized within anti infective agents for microbiology, host pathogen interaction studies, and antibacterial discovery workflows focused on Gram positive organisms. Derived from the glycopeptide scaffold represented by vancomycin class chemistry, it is primarily used to investigate bacterial cell envelope vulnerability and resistance biology, with reported mechanistic actions that include inhibition of cell wall biosynthesis, perturbation of membrane potential, and interference with regulatory signaling processes such as ArlS associated kinase activity in relevant bacterial systems, thereby supporting multi mechanism interrogation in phenotypic and target informed assays. In vitro activity is generally described as strong against susceptible Gram positive strains, including resistant phenotypes, with potency frequently observed from low concentration antibacterial windows spanning high nanomolar to low micromolar equivalent activity ranges depending on strain background, assay medium, inoculum, and endpoint definition, and published microbiological profiling has also reported very low MIC behavior in selected Bacillus anthracis test strains under specific conditions. In biomedical research settings, this molecule is typically applied in broth microdilution susceptibility platforms, time kill kinetics, membrane integrity and depolarization assays, cell wall stress response studies, resistance selection experiments, and translational preclinical infection models designed to map pharmacology response relationships in nonclinical systems, while concentrations or doses used in experiments typically depend on specific experimental designs, organism characteristics, and research objectives.